You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
Response to pembrolizumab in a heavily treated patient with metastatic ovarian carcinosarcoma
|
|---|---|
| Published in |
Gynecologic Oncology Research and Practice, August 2018
|
| DOI | 10.1186/s40661-018-0063-3 |
| Pubmed ID | |
| Authors |
Graziela Zibetti Dal Molin, Carina Meira Abrahão, Robert L. Coleman, Fernando Cotait Maluf |
| Abstract |
Ovarian carcinosarcoma is a rare malignancy associated with a high rate of cancer-related mortality even at early stages. Guidelines for systemic treatment have been difficult to establish because the disease is commonly excluded from prospective clinical trials. Ovarian carcinosarcoma is usually managed as high-grade epithelial ovarian cancer despite major histologic differences. Owing to the rarity and poor prognosis of ovarian carcinosarcoma, salvage treatments and their efficacy have been poorly described. A patient heavily treated for ovarian carcinosarcoma showed an objective response to an immune checkpoint inhibitor, pembrolizumab. Pembrolizumab in this patient appeared to provide tumor control in multifocal metastatic sites. Pembrolizumab should be evaluated in prospective trials for the treatment of ovarian carcinosarcoma and further work is needed to identify patients most likely to respond to this type of intervention. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 14 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 14 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Other | 4 | 29% |
| Student > Postgraduate | 2 | 14% |
| Student > Doctoral Student | 1 | 7% |
| Unspecified | 1 | 7% |
| Researcher | 1 | 7% |
| Other | 1 | 7% |
| Unknown | 4 | 29% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 5 | 36% |
| Unspecified | 1 | 7% |
| Nursing and Health Professions | 1 | 7% |
| Biochemistry, Genetics and Molecular Biology | 1 | 7% |
| Economics, Econometrics and Finance | 1 | 7% |
| Other | 1 | 7% |
| Unknown | 4 | 29% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 28 August 2018.
All research outputs
#20,663,600
of 25,385,509 outputs
Outputs from Gynecologic Oncology Research and Practice
#30
of 36 outputs
Outputs of similar age
#265,618
of 341,495 outputs
Outputs of similar age from Gynecologic Oncology Research and Practice
#3
of 4 outputs
Altmetric has tracked 25,385,509 research outputs across all sources so far. This one is in the 10th percentile – i.e., 10% of other outputs scored the same or lower than it.
So far Altmetric has tracked 36 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 24.2. This one scored the same or higher as 6 of them.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 341,495 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 12th percentile – i.e., 12% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 4 others from the same source and published within six weeks on either side of this one.